Phase 1 Study Evaluating Safety, Dosage, and Early Effectiveness of LY4152199 IV in Adults with Previously Treated B-cell Malignancies

What this Trial Is About

Researchers are studying LY4152199, a drug given by intravenous infusion, in adults with previously treated B-cell malignancies, including follicular lymphoma and diffuse large B-cell lymphoma. This Phase 1 study aims to find the best dose while evaluating the safety and early effectiveness of LY4152199 in participants who have relapsed or refractory disease. Participants may continue receiving the drug until the study ends. Participants receive escalating doses of LY4152199 administered intravenously during dose escalation and dose optimization phases. The study includes different cohorts focused on specific lymphoma types. LY4152199 is given repeatedly, with dose levels adjusted based on safety and response. Treatment continues until disease progression, unacceptable toxicity, or study completion. During the study, participants undergo regular clinical visits with laboratory monitoring and assessments to track safety, drug levels, and treatment response. Researchers measure dose-limiting toxicities, pharmacokinetics, overall response rate, duration and time to response, and progression-free survival. Participants must comply with ongoing evaluations and visits for the entire participation period, which may last up to several years depending on individual treatment duration and follow-up.

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )